Table 2.
Incident Comorbidities after 10 Years of Follow-up in Older Five-Year Early Breast Cancer Survivors and Matched Comparison Cohort
| Breast Cancer Survivor Cohorta (n = 1,361) |
Comparison Cohortb (n = 1,361) |
Adjusted Hazard Ratio |
|||||
|---|---|---|---|---|---|---|---|
| No. | % | No. | % | Adj HRc | (95 % CI) | ||
| Any incident comorbidity acquired in 10 year observation period | 870 | 64 | 911 | 67 | 1.0 | (0.93,1.1) | |
| Frequency of Incident Comorbid Conditions and Adjusted Hazard Ratios from Individual Modelsd (index weight) | |||||||
| Myocardial infarction | (1) | 91 | 6.7 | 123 | 9.0 | 0.75 | (0.57,0.99) |
| Congestive heart failure | (1) | 197 | 14 | 219 | 16 | 0.92 | (0.76,1.1) |
| Peripheral vascular disease | (1) | 76 | 5.6 | 93 | 6.8 | 0.84 | (0.62,1.1) |
| Cerebrovascular disease | (1) | 145 | 11 | 176 | 13 | 0.85 | (0.68,1.1) |
| Dementia | (1) | 248 | 18 | 257 | 19 | 1.0 | (0.85,1.2) |
| Chronic pulmonary disease | (1) | 112 | 8.2 | 127 | 9.3 | 0.92 | (0.72,1.2) |
| Connective tissue disease | (1) | 29 | 2.1 | 24 | 1.8 | 1.3 | (0.74,2.2) |
| Ulcer disease | (1) | 46 | 3.4 | 53 | 3.9 | 0.92 | (0.62,1.4) |
| Diabetes | (1) | 149 | 11 | 117 | 8.6 | 1.4 | (1.1,1.8) |
| Mild liver disease | (1) | 8 | 0.59 | 10 | 0.73 | 0.85 | (0.33,2.1) |
| Hemiplegia | (2) | 35 | 2.6 | 50 | 3.7 | 0.72 | (0.47,1.1) |
| Moderate or severe renal disease | (2) | 79 | 5.8 | 83 | 6.1 | 1.0 | (0.74,1.4) |
| Diabetes with end organ damage | (2) | 76 | 5.6 | 66 | 4.9 | 1.2 | (0.88,1.7) |
| Leukemia, lymphoma or tumore | (2) | 123 | 9.0 | 115 | 8.7 | 1.1 | (0.87,1.5) |
| Moderate or severe liver disease | (3) | 4 | 0.29 | 5 | 0.37 | 0.82 | (0.22,3.1) |
| AIDS | (6) | 0 | 0 | 0 | 0 | – | – |
| Metastatic solid tumor | (6) | 37 | 2.7 | 31 | 2.3 | 1.2 | (0.77,2.0) |
| Pulmonary embolismf | (1) | 11 | 0.81 | 19 | 1.4 | 0.61 | (0.29,1.3) |
| Osteoporotic fracturef | (1) | 231 | 17 | 238 | 17 | 1.0 | (0.83,1.2) |
Older five-year survivors diagnosed 1990–1994 with early stage I and II breast cancer at age 65 or older followed for 10 years beginning five years after index date (date of breast cancer diagnosis).
Comparison cohort matched for health system and age, who were free of breast cancer at matched index date and followed for 10 years beginning five years after index date.
Hazard ratio (HR) adjusted for study site location, age, and presence of prevalent comorbidity. CI = Confidence Interval.
Women may be counted in multiple comorbidities.
Prevalent breast cancer at index date excluded in modified Charlson Comorbidity Index (CCI).
Comorbidities added to original CCI to create modified CCI (Charlson et al 1987).